Lessons learned from clinical trials in SLE

Autoimmunity Reviews

Volumn 6, Issue 4, 2007, Pages 209-214

  Strand, Vibeke ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Clinical trials; Flare; Outcome measures; Renal disease; Systemic lupus erythematosus

Indexed keywords

BELIMUMAB; EPRATUZUMAB; RITUXIMAB;

CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; MEDICAL PRACTICE; OUTCOME ASSESSMENT; PATIENT SELECTION; QUALITY OF LIFE; REPRODUCIBILITY; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS;

EID: 33847029062     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.08.002     Document Type: Review

References (37)

1. Strand V., Gladman D., Isenberg D., Petri M., Smolen J., and Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 26 (1999) 490-497
2. Smolen J., Strand V., Cardiel M., et al. Randomized clinical trials and longitudinal observational studies in SLE: consensus on a preliminary core set of outcome domains. J Rheumatol 26 (1999) 504-507
3. Strand V. Issues in Drug Development in SLE: Clinical Trial Design, Outcome Measures and Biomarkers. In: Wallace D.J., and Hahn G.H. (Eds). Dubois' lupus erythematosus. 7th ed. (2006), Williams and Wilkins, Baltimore 1317-1332 [chapter 68]
4. Gordon C., Sutcliffe N., Skan J., Stoll T., and Isenberg D.A. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 42 (2003) 1372-1379
5. Ward M.M., Marx A.S., and Barry N. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 27 (2000) 654-670
6. Strand V. Clinical trial design in systemic lupus erythematosus: Lessons learned and future directions. Lupus 13 (2004) 1-6
7. Merrill J. Measuring disease activity in systemic lupus: progress and problems. J Rheumatol 29 (2002) 2256-2257
8. Isenberg D.A., Gordon C., and BILAG Group. British Isles Lupus Assessment Group. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 9 (2000) 651-654
9. Vitali C., Bencivelli W., Mosca M., Carrai P., Sereni M., and Bombardieri S. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol 26 (1999) 498-501
10. Gladman D.D., Goldsmith C.H., Urowitz M.B., et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 27 (2000) 373-376
11. Schiffenbauer J., Chakravarty E., and Strand V. Evidence based treatment of systemic lupus erythematosous. In: Tugwell P., Shea B., Brooks P., Boers M., Simon L., Strand V., and Wells G. (Eds). Evidence Based Rheumatology (2003), British Medical Journal, London 97-140
12. Rahman P., Gladman D.D., Ibanez D., and Urowitz M.B. Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Lupus 10 (2001) 418-423
13. Gladman D.D., Urowitz M.B., Fortin P., et al. SLICC conferences on assessment of lupus flare and QOL measures in SLE. J Rheumatol 23 (1996) 1953-1955
14. Strand V., and Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoeconomics Outcomes Rev 5 (2005) 317-326
15. Strand V., Aranow C., Cardiel M.H., et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 12 (2003) 677-686
16. Chang E.R., Abrahamowicz M., Ferland D., and Fortin P.R. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients' or physicians' evaluations of recent lupus activity. J Rheumatol 29 (2002) 2350-2358
17. Kalunian K.C., Davis Jr. J.C., Merrill J.T., Totoritis M.C., and Wofsy D. IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 3251-3258
18. Boumpas D.T., Furie R., Manzi S., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003) 719-727
19. Grammer A.C., Slota R., Fischer R., et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 112 (2003) 1506-1520
20. Ho A., Magder L.S., Barr S.G., and Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44 (2001) 2342-2349
21. Bootsma H., Spronk P., Derksen R., et al. Prevention of relapses in systemic lupus erythematosus. Lancet 345 (1995) 1595-1599
22. Walz LeBlank B.A.E., Gladman D.D., and Urowitz M.B. Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol 21 (1994) 2239-2241
23. Tseng C., Buyon J., Kim M., et al. Moderate dose steroids prevent severe flares in a prospective multicenter study of serologically active, clinically stable SLE patients. Arthritis Rheum 48 (2003) S260
24. Petri M., Kim M.Y., Kalunian K.C., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353 (2005) 2550-2558
25. Buyon J.P., Petri M.A., Kim M.Y., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142 (2005) 953-962
26. Alarcon-Segovia D., Tumlin J.A., Furie R.A., et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 48 (2003) 442-454
27. Linnik M.D., Hu J.Z., Heilbrunn K.R., Strand V., Hurley F.L., and Joh T. LJP 394 Investigator Consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 52 (2005) 1129-1137
28. Wallace D.J., and Tumlin J.A. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 13 (2004) 323-327
29. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
30. Sfikakis P.P., Boletis J.N., and Tsokis G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17 (2005) 550-557
31. Lajaunias F., Ida A., Kikuchi S., et al. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus. Arthritis Rheum 48 (2003) 1612-1621
32. Doerner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., and Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 (2006) R7
33. Stohl W. A therapeutic role for BLyS antagonists. Lupus 13 (2004) 317-322
34. Petri M., Stohl W., Chatham W., et al. BLyS plasma concentrations correlate with disease activity and levels of Anti-dsDNA autoantibodies and immunoglobulins (IG) in a SLE patient observational study. Arthritis Rheum 48 (2003) S655
35. Petri M., Wallace D.J., Stohl W., et al. SLE patients with active production of anti-nuclear autoantibodies (ANA) have distinct patterns of lupus activity and peripheral B-cell biomarkers compared to ANA negative patients. Ann Rheum Dis 65 (2006) FRI0231
36. Wallace D.J., Lisse J., Stohl W., et al. Belimumab (BmAb), a fully human monoclonal antibody to b-lymphocyte stimulator (BLyS), shows bioactivity and reduces systemic lupus erythematosus disease activity. Ann Rheum Dis 65 (2006) OP0029
37. Furie R., Lisse J., Merrill J.T., et al. Multiple SLE disease activity measures in a multi-center phase 2 SLE trial demonstrate belimumab (fully human monoclonal antibody to b-lymphocyte stimulator [BLyS]) improves or stabilizes SLE activity. Ann Rheum Dis 65 (2006) OP0030